Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)

NCT01148797 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Colchicine Resistant/Intolerant Familial Mediterranean Fever

Interventions

DRUG: Canakinumab

Sponsor

Novartis Pharmaceuticals